Compare Funko Inc (FNKO) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Funko Inc vs Repligen Corporation Common Stock — how do they compare? Funko Inc trades at $6.35 (market cap $365.09M), while Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is far larger — about 30.5× Funko Inc's market cap, and Funko Inc is more actively traded (435,098 versus 1,259,263). Which is the better fit depends on your goals — on Pluang, investors hold Funko Inc for 33 Days and Repligen Corporation Common Stock for 0 Days on average.
| FNKO | RGEN | |
|---|---|---|
Market Cap | $365.09M | $11.14B |
Volume | 435,098 | 1,259,263 |
Sector | Consumer Cyclical | Health |
52-Week High | $7.10 | $194.57 |
52-Week Low | $2.81 | $102.87 |
Typical Hold Time | 33 Days | 0 Days |
Enterprise Value | $585.74M | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNKO trades at $6.35, down 1.7% today, with a bullish technical signal from moving averages despite overbought RSI readings. The company shows improving fundamentals with Q2 2026 earnings beating expectations, revenue growth of 7% year-over-year, and raised EBITDA guidance to $105 million. Analyst consensus is mixed with 42.9% buy ratings and a $7.58 price target, representing 19% upside potential from current levels.
Investment outlook remains cautiously optimistic as FNKO demonstrates operational improvements with margin expansion and debt reduction. Key risks include negative net income margins, volatile cash flow patterns, and competitive pressures in the collectibles market. The stock offers value with a low P/S ratio of 0.39x and attractive EV/EBITDA of 6.84x, but requires sustained profitability to justify further appreciation.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
